US needs price controls for COVID-19 drugs, employer advocacy group says

The U.S. government should set prices for COVID-19 drugs and vaccines to avoid price-gouging, an advocacy group for employers told Bloomberg.

The Employers' Prescription for Affordable Drugs said Medicare should determine fair prices for COVID-19 drugs and vaccines and pointed to Gilead's remdesivir as an example of an overpriced drug. The FDA approved remdesivir as a COVID-19 treatment in October. The drug costs private health plans more than $3,00 per treatment course, Bloomberg reported.